Myriad Genetics Advances Prostate Cancer Care with Addition

Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 -- Myriad Genetics, Inc., a leader in...
-Today at 07:06 am- MarketScreener

Related Keywords

United States , American , Glenn Farrell , Matt Scalo , Terry White , Genetics Inc , University Of Utah , Nasdaq , National Comprehensive Cancer Network , Exchange Commission , Huntsman Cancer Institute , American Society Of Clinical Oncology Annual Meeting , Absolute Risk Reduction , Prostate Cancer Prognostic Test , Jonathan Tward , Clinical Oncology Annual Meeting , National Comprehensive Cancer , General Manager , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Absolute Benefit , Androgen Deprivation Therapy , Radiation Therapy , Newly Diagnosed Prostate , Markets ,